一种通用的抗体阻断蛋白质,可使抗体活性的pH可切换激活
Lieuwe Biewenga1,2, Robin Vermathen1,2, Bas J H M Rosier1,2
1Laboratory of Chemical Biology, Department of Biomedical Engineering, Eindhoven University of Technology, 5600 MB Eindhoven, The Netherlands.
ACS chemical biology
|December 18, 2023
概括
研究人员开发了一种pH可切换蛋白M变体 (蛋白M-8his),可逆控制抗体活性. 这一创新能够通过调节基于pH值的抗体结合,在抗体净化和向治疗中实现新的应用.
科学领域:
- 生物化学 生物化学
- 蛋白质工程是指蛋白质工程.
- 免疫学 免疫学 免疫学
背景情况:
- 对抗体活性的可逆控制对于治疗和诊断应用至关重要.
- 蛋白M与IgG的Fv域结合,阻断抗原结合,但其解离是不可逆转的.
- 这种不可逆转性限制了其作为可调的抗体亲和反应剂或分子面具的使用.
研究的目的:
- 设计一种具有可逆IgG结合能力的蛋白M变体.
- 开发一种可切换pH的亲和反应剂,用于抗体的净化和调制.
- 探索这种变体在有针对性的治疗应用中的潜力.
主要方法:
- 在蛋白M的Fv结合接口上引入8个histidine残留物.
- 工程变异的依赖pH的IgG结合性能的表征.
- 评估蛋白质M-8his变体作为亲和树脂和阻断抗体活性.
主要成果:
- 工程蛋白M-8his变体表现出pH可切换的IgG结合.
- 这种变体作为一种通用亲和树脂,用于净化各种抗体格式,包括IgG,Fabs和scFvs.
- 蛋白M-8his显示了治疗抗体的pH依赖性阻断,使得选择性细胞在pH值6.0时准.
结论:
- 蛋白质M-8his变体为可逆抗体控制提供了一个新的解决方案.
- 它是用于抗体净化和开发向治疗的多功能工具.
- 可切换pH的抗体结合为生物技术和医学中精确控制开辟了新的途径.
更多相关视频
相关概念视频
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Antibody Structure
60.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.2K
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K
Antibody Structure and Classes
919
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
919
Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
Humoral Immune Responses
72.8K
Overview
72.8K


